A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): an open-label, single-arm, single-centre, phase II trial

Venkataramanan Srinivasan, Victoria Homer, Darren Barton, Abigail Clutterbuck-James, Siân Jenkins, Claire Potter, Kristian Brock, Ann Logan, Donna Smith, Lars Bruce, Zsuzsanna Nagy, Simon P Bach
doi: https://doi.org/10.1101/2023.08.27.23294691

Article usage

Article usage: August 2023 to November 2024

AbstractFullPdf
Aug 2023164023
Sep 20231993127
Oct 20231081014
Nov 202379510
Dec 20234109
Jan 202435412
Feb 20244708
Mar 202452410
Apr 20249049
May 20245549
Jun 20242922
Jul 20245808
Aug 20243404
Sep 20243426
Oct 20242118
Nov 20242402
Back to top
Posted August 29, 2023.
Download PDF
Data/Code
Email
A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): an open-label, single-arm, single-centre, phase II trial
Venkataramanan Srinivasan, Victoria Homer, Darren Barton, Abigail Clutterbuck-James, Siân Jenkins, Claire Potter, Kristian Brock, Ann Logan, Donna Smith, Lars Bruce, Zsuzsanna Nagy, Simon P Bach
medRxiv 2023.08.27.23294691; doi: https://doi.org/10.1101/2023.08.27.23294691
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area